Foghorn Therapeutics & Eli Lilly Halt Fhd-909 Development Following Phase I Data
Foghorn Therapeutics and Eli Lilly halted development of FHD-909 after Phase I trial data showed insufficient efficacy, ending their collaboration. Foghorn will cut 40% of its workforce and focus on four proprietary programs, funded until mid-2029. According to Norstella, early-phase trial failures are increasing in the industry.
How this was made
The 30-second read
Why it matters
The news is expected to depress FOXR sharply and cause modest downside for LLY, reflecting the loss of a pipeline asset and partnership.
Market read
First‑report of a major program termination and workforce cut, creating actionable downside risk for FOXR and modest impact for LLY.
What to watch
Lilly may redirect resources to higher‑probability assets, mitigating the loss of this specific collaboration.
Background
The article reports the first public disclosure of the program halt and restructuring, providing fresh corporate‑action news for both companies.
Ticker impact
Eli Lilly ended its collaboration with Foghorn on the SMARCA2 degrader program, removing a potential future product from its pipeline.
slight downside pressure as the market adjusts expectations for the SMARCA2 program
Lilly's loss is limited to a single partner program; the broader business is unaffected, so impact is modest.
Market effects
Biotech sector may see broader risk aversion as early‑stage oncology failures are highlighted.
US biotech indices could face slight pullback; European partners may see neutral effect.
Limited to biotech investors; no broad market impact.
Counterpoint
The termination frees Foghorn to focus resources on four promising programs, potentially improving long‑term value.
Key entities
- companyFoghorn Therapeutics Inc.
Biotech firm developing SMARCA2 degraders.
- companyEli Lilly and Company
Pharmaceutical giant and partner in the SMARCA2 program.
